NHS Electronic Prescription Service Patient Nomination Principles

2026/27 Community Pharmacy Contractual Framework Settlement and Reform

The 2026/27 funding agreement and strategic goals for the community pharmacy sector in England. A primary feature of this settlement is a 10.3% budget increase, bringing total investment to £3,636 million by merging several existing financial streams. Beyond direct funding, the deal introduces independent prescribing into core services and permits pharmacies to pause operations for four hours monthly for staff training. While the representative body accepted the offer to prevent industry collapse, they emphasize that further long-term reform and investment remain necessary to address persistent workload and financial pressures. To assist with this transition, the documents detail upcoming implementation steps, including regional roadshows and new tools for estimating pharmacy income. Finalizing this arrangement marks the beginning of a broader Community Pharmacy Strategy intended to stabilize the supply of medicines and enhance primary care.

NHS Electronic Prescription Service Patient Nomination Principles

The regulatory framework and ethical standards for the NHS Electronic Prescription Service nomination process. It emphasizes that patients hold absolute autonomy over which pharmacy or dispenser receives their prescriptions, prohibiting healthcare providers from using incentives or coercion to influence these decisions. Staff across all medical settings must ensure patients are fully informed of their right to change or remove nominations at any time without restriction. To maintain system integrity, providers are required to follow auditable procedures for obtaining consent and must reconfirm choices during significant changes, such as pharmacy ownership transfers. Finally, the guidelines establish clear accountability measures and complaint pathways to protect patient choice and ensure fair competition among dispensing contractors.

The NEW NHS Framework

This official policy framework outlines a strategic shift in the English health system toward a neighborhood-centered model of care. By integrating NHS services with local government and social care, the initiative aims to move medical focus from hospitals to preventative, community-based environments. The document establishes specific national goals for improving GP access, managing long-term conditions like frailty and dementia, and reducing unnecessary emergency admissions. It introduces new contractual structures, such as Integrated Health Organizations, and details plans for 250 neighborhood health centers to serve as local hubs. Ultimately, the framework seeks to restore public confidence by creating a more accessible, less bureaucratic, and digitally integrated healthcare experience.

Inappropriate EPS Nomination and Service Direction

This podcast outlines efforts by Community Pharmacy England to address and eliminate inappropriate Electronic Prescription Service (EPS) nominations and the unauthorized direction of patient services. By collaborating with NHS England and the British Medical Association, the organization is implementing stricter regulatory guidelines to ensure that medical providers do not manipulate where patients receive their medications. Key updates include a 2026/27 GP Contract amendment that requires doctors to reconfirm a patient’s chosen pharmacy when issuing new prescriptions. These measures aim to protect patient choice and prevent IT systems from automatically selecting dispensers without explicit consent. Ultimately, the initiative seeks to maintain professional integrity and transparency across the community pharmacy sector.

Drug Tariff Category H Overview

Starting in March 2026, the Department of Health and Social Care will implement Category H into the official Drug Tariff to reform how certain medicines are reimbursed. This new classification targets products currently in Category C that are provided by multiple manufacturers, shifting away from prices based on a single brand's list price. Instead, reimbursement rates will be determined by actual market data collected from suppliers to better reflect true pharmacy costs. While the government intends to improve the distribution of medicine margins, representative bodies like Community Pharmacy England have expressed significant concern. They argue that these imposed changes could further strain pharmacy funding and potentially destabilize an already fragile medicine supply chain.